SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

SBFM RSS Feed
Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, GREGG THE GREEK, Upset Wookie
Search This Board: 
Last Post: 11/18/2017 8:08:07 AM - Followers: 345 - Board type: Free - Posts Today: 1








 



 

 


"The Future Of Medicine"
 

 




 
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 





 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 
 


Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697

 

Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.


Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options

 
 
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.







Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 







 
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).


Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug




They have been changing the timeline for years Now “mid/late 2017” now to start phase 1. Anyone can review past quarterlies to see that it keeps on sliding to the right. Share structure will be raised to 3B as stated here http://www.sec.gov/Archives/edgar/data/1402328/000135448816006700/sbfm_10k.htm Yes, dilution is going nuts, and I sure wouldn’t mind the 35% discount. Pretty much the saga continues. Imo.

Just a few random excerpts. Mostly for my own notes.

1st Q 2016

Common Stock, $0.001 per share; Authorized 500,000,000 Shares; Issued and outstanding 232,876,353 and 198,265,118 at March 31, 2016 and December 31, 2015 respectively


Weighted Average Common Shares Outstanding
215,596,040 78,942,780

Note 1 – Descriptions of Business
In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Canada is currently working on securing a Drug Establishment License from Health Canada and signing manufacturing, marketing, sales and distribution contracts for various generic pharmaceuticals for sale in Canada and overseas.

During the last three month period the Company has continued to raise money through stock sales and borrowings.

Note 4 – Notes Payable

A Note having a Face Value of $19,142 was entered into on December 31, 2015. This Note accrues interest at the rate of 12% per annum and a total of $574 in accrued interest was expensed during the quarter ended March 31, 2016. This is a Non-convertible Note due on December 31, 2016.

A Note having a principal balance of $83,000 as of December 31, 2015 was fully converted, together with $3,320 of accrued interest thereon, into $0.001 par value Common Stock during the three month period ended March 31, 2016. In connection therewith, 9,906,049 shares of $0.001 par value Common Stock valued at $146,658 were issued generating a loss of $63,658 on conversion.

A Note having a Face Value $203,036 with interest of 12% is due June 30, 2016. This Note is convertible after December 31, 2015 into $0.001 par value Common Stock at a price 35% below market value. During the period ended March 31, 2016, a total of $38,036 in principal was converted into $0.001 par value Common Stock leaving a principal balance of $165,000. In connection this conversion, 7,705,186 shares of $0.001 par value Common Stock valued at $231,156 were issued generating a loss of $193,120 on conversion.
On February 18, 2016, the Company received monies in exchange for a note due November 18, 2016 having a Face Value of $85,000 and accruing interest at 8%. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
Note 5 – Notes Payable Related Entity
On October 8, 2015, the Company acquired from Advanomics Corporation (a related party) U.S. Patent Number 8,236,935 (the “Patent”) for the anticancer compound, Adva-27a, which includes all rights to this intellectual property within the United States in exchange for an interest-free note payable for $4,320,000 with annual payments of $360,000 due and payable on or before December 31, commencing in 2016 and continuing until paid in full. The note is collateralized by the Patent. Pursuant to an amendment agreement effective December 28, 2015, this note was cancelled and replaced with a new note having a face value of $210,519, comprised of $155,940 in principal amount which is the seller’s (Advanomics Corporation, a related party) book value of the Patent plus $54,579 as an adjustment for the currency exchange difference, which was expensed immediately. This new, interest-free Note is automatically convertible into a fixed number of 80,968,965 shares of the Company’s $0.001 par value Common Stock upon the Company completing an increase in its authorized capital such that a sufficient number of Common shares is available for issuance. However, if the Company does not increase its capitalization within 90 days from the date of the Note, interest will begin to accrue at the rate of 10% per annum.

On December 28, 2015, the Company acquired from Advanomics Corporation (a related party) the worldwide issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Patents”) for the anticancer compound, Adva-27a, which include all worldwide rights to this intellectual property in exchange for a note payable for $12,822,499, with interest accruing at 2% per year beginning January 1, 2016 and quarterly payments of $70,000 plus interest commencing the end of March 2016 and continuing until December 2020 when the entire principal balance and all accrued interest will be due. The note is collateralized by the Patents. Pursuant to an amendment agreement, effective December 28, 2015, this note was cancelled and replaced with a new convertible note having a face value of $624,875, comprised of $462,870 in principal amount which is the seller’s (Advanomics Corporation, a related party) book value of the Patents, plus a $162,005 amount as an adjustment for the currency exchange difference, which was expensed immediately. This new, interest-free Note is automatically convertible into a fixed number of 240,336,451 shares of $0.001 par value Common Stock upon the Company completing an increase in its authorized capital such that a sufficient number of Common shares is available for issuance. However, if the Company does not increase its capitalization within 90 days from the date of the Note, interest will begin to accrue at the rate of 10% per annum.

Note 6 – Issuance of Common Stock

At March 31, 2016 the Company had issued and outstanding 232,876,353 shares of $0.001 par value Common Stock. During the three months ended March 31, 2016, the Company issued a total of 34,611,235 shares of $0.001 par value Common Stock. Of these, 17,611,235 shares having a market value of $377,814 have been issued reducing debt by $121,036 and interest payable by $3,120 and generating a loss on conversion of $253,658 for the period ended March 31, 2016. The Company issued 7,000,000 shares of $0.001 par value Common Stock for $105,000 Canadian (approximately $79,128 US). For services to be rendered, the Company issued 10,000,000 shares of $0.001 par value Common Stock having a market value of $100,000 or $0.01 per share, to an unaffiliated company that is assisting the Company in the development of manufacturing, marketing, sales and distribution contracts for various generic pharmaceuticals and biomedical products in Canada. These services are for a two year period and will be expensed ratably over a 24 month period commencing April 1, 2016.

Note 7 – Issuance of Series “B” Preferred Stock

During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock. The Series “B” Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All 500,000 shares of Series “B” Preferred Shares were issued to the CEO of the Company in exchange for services valued at $50,000.
Note 8 – Earnings (Loss) Per Share

Earnings (loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has adopted ASC 260 (formerly SFAS128), “Earnings per Share”. Other than the shares to be issued for the purchased patents as specified under Note 5 above, the Company has no potentially dilutive instruments outstanding.

Note 9 – Financial Statements

For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission and the audited financial statements included therein.


Note 10 – Income Taxes


Certain members of the Company’s management, including Dr. Steve N. Slilaty, our President, CEO and a Director and Camille Sebaaly, our CFO, Secretary and a Director, hold similar positions with Advanomics Corporation, the seller of the Adva-27a patents recently acquired by the Company (See Note 5 above).


The Company’s principal place of business is located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada, H3N 1R4. This is also the location of Advanomics, who continues to provide this space to the Company on a rent free basis as of the date of this Report. Dr. Steve N. Slilaty, the Company’s Chief Executive Officer and a Director, is an Officer, Director and principal shareholder of Advanomics.


Note 12 – Subsequent Events
In April 2016, the Directors of the Company were issued an aggregate of 36,000,000 shares of the Company’s $0.001 par value Common Stock (12,000,000 shares per Director) in consideration for services rendered through December 31, 2015 valued at $36,000.
Our principal place of business is located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada H3N 1R4. Our phone number is (514) 764-9698 and our website address is www.sunshinebiopharma.com.


We have not been subject to any bankruptcy, receivership or similar proceeding.

Comparison of Results of Operations for the three months ended March 31, 2016 and 2015 (excerpt)
General and administrative expenses during the three month period ended March 31, 2016 were $69,682, compared to general and administrative expense of $124,825 incurred during the three month period ended March 31, 2015, a decrease of $55,143. This decrease is primarily attributable to the elimination of the $50,000 license fee we incurred during 2015 that we did not incur in the three months ended March 31, 2016 because we acquired the patent rights which were the subject of the license fee.

As a result, we incurred a net loss of $305,294 ($0.00 per share) for the three month period ended March 31, 2016, compared to a net loss of $294,367 ($0.00 per share) during the three month period ended March 31, 2015.

Acquisition of Patents (excerpt)

...we executed the aforesaid amendments to the original Patent Purchase Agreements which provided for (i) reduction of the purchase price of the Patents from $17,142,499 to $618,810, the Advanomics book value of the Patents, (ii) elimination of all cash payments obligations, and (iii) automatic convertibility of the new promissory notes for the new purchase price into an aggregate of 321,305,415 shares of Common Stock upon our increasing our authorized capital such that this number of Common Shares can be issued.

GMP Manufacturing (excerpt)
In June 2015 we received a sample of the scale-up manufacturing process for evaluation and confirmation of adherence to specifications. Based upon our laboratory analyses, the sample meets all of the required chemical, physical and biological specifications. The amount of material (the “Yield”) generated by this pilot run was found to be significantly lower than anticipated and we are currently working towards finding possible solutions to increase the Yield. If the timetable for generating the 2-kilogram quantity is met, of which there can be no assurance, and subject to receipt of the necessary financing, also for which no assurances can be provided, we expect to move into Phase I of our clinical trials in mid to late 2017.

Pursuant to the terms of the Lonza Agreement, Lonza will manufacture our drug in accordance with current Good Manufacturing Practices (“cGMP”) in compliance with the regulations applicable in the U.S., Canada, Europe and other countries around the world relating to the manufacturing of medicinal products for human use. Lonza will build a master drug file for our Adva-27a drug and will have it ready for filing with regulatory authorities as may be required to secure ultimate drug approval. The Lonza Agreement provides for us to maintain one representative of our Company at their facility during the manufacturing process. Quality assurance and control is the responsibility of both Lonza and us during the process.
http://www.sec.gov/Archives/edgar/data/1402328/000135448816007274/sbfm_10q.htm

http://www.sec.gov/Archives/edgar/data/1402328/000135448816006700/sbfm_10k.htm


=================================

January 29, 2014 S-4
https://www.sec.gov/Archives/edgar/data/1402328/000135448814000422/sbfm_s4.htm

followed again by another withdrawel
https://www.sec.gov/Archives/edgar/data/1402328/000135448814002116/sbfm_rw.htm

RCMP Canada.
http://www.rcmp.gc.ca/en
http://www.antifraudcentre-centreantifraude.ca/reportincident-signalerincident/index-eng.htm

SEC Complaint process
https://denebleo.sec.gov/TCRExternal/index.xhtml
================================================================== 



 



http://sunshinebiopharma.com/investor/press-releases/
 
 
 
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290, colleen.floreck@lonza.com
Constance Ward, +41 61 316 8840, constance.ward@lonza.com
 
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/nansha-china.aspx

Visp Switzerland
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/visp-switzerland.aspx




SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals
 
Chairman and CEO Dr. Steve N. Slilaty Interview 

FDA links:

http://clinicaltrials.gov/ct2/seac/index

 
 

 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

 
Intellectual Property

 
We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
 
 
Advanomics

http://www.canada-companies-info.com/advanomics-corporationcorporation-advanomics-65q2
Advanomics Corporation, the Parent Company of Sunshine Biopharma
 

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada

Tel: 514-764-9698
Fax: 514-764-9699
info@advanomics.com

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:

Adva-27a

Difluoro-Etoposide™
Entering Phase I later this year (Lead Compound)

 

Adva-R46

RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase

 

Adva-33c

Difluoro-Carboplatin™
Currently in preclinical phase



 



SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

http://corporatestock.com




Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada
Tel: 514-764-9698
Fax: 514-764-9699

http://sunshinebiopharma.com
info@sunshinebiopharma.com


 

 



 


 

 












































































 
SureTrader
Interactive Brokers Advertisement
SBFM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SBFM News: Quarterly Report (10-q) 11/15/2017 10:23:08 AM
SBFM News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/13/2017 12:11:31 PM
SBFM News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 09:56:57 AM
SBFM News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 09:46:20 AM
SBFM News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 09:29:36 AM
PostSubject
#31571  Sticky Note They have been changing the timeline for years BooDog 05/10/16 07:16:53 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Dan (Retired) 10/09/13 10:52:01 AM
#37005   I agree! Maybe even up to 0.20. And White Shadow 11/18/17 08:08:07 AM
#37004   To others points about the purchasing of the iluvcanada 11/17/17 11:11:39 PM
#37002   Been hearing that for over a yr. GREGG THE GREEK 11/16/17 08:36:21 PM
#37001   ??????Get ready for the tripple cherries folks ?????? Cash Monster 11/16/17 05:36:44 PM
#36996   You were bang on, 200 DMA tested today, Riley34 11/16/17 01:02:15 PM
#36990  Restored Get out, this piece of crap will collapse,the Cash Monster 11/15/17 03:16:53 PM
#36987   These fraudsters are all going to jail for Cash Monster 11/15/17 03:07:13 PM
#36986  Restored Scam craphead camille sold unregistered shares of advanomics Cash Monster 11/15/17 03:03:56 PM
#36985  Restored The turd crap Slilaty screwed investors millions and Cash Monster 11/15/17 03:02:18 PM
#36984   Thanks for the ‘scam alert’ wow Now know! gangsterflavor 11/15/17 03:01:22 PM
#36983   <<Scam Alert>>This company is a scam, and the Cash Monster 11/15/17 02:59:05 PM
#36982   To my understanding, the bought the patent for Riley34 11/15/17 02:41:24 PM
#36981   Sorry, my opinion what not meant to be Pennyboy20 11/15/17 01:45:19 PM
#36980   Thank you for the corrections, that's what I iluvcanada 11/15/17 01:23:15 PM
#36979   In my opinion (not a doctor or scientist), Pennyboy20 11/15/17 12:16:20 PM
#36978   The valuation payment was in last Q-10. It Riley34 11/15/17 11:43:01 AM
#36977   Well I haven't posted in a bit, but iluvcanada 11/15/17 11:29:57 AM
#36976   Well look at that, they made it on Riley34 11/15/17 10:45:52 AM
#36975   You beat me to it good sir! Let's Upset Wookie 11/15/17 10:41:11 AM
#36974   Nope! 10-q is out. CashMoney75 11/15/17 10:31:50 AM
#36973   Quarterly will be late as per their release Riley34 11/15/17 10:16:18 AM
#36972   I will be watching the EDGAR system today Upset Wookie 11/15/17 09:39:01 AM
#36971   Im buying on ANY dips tomorrow!! This will gangsterflavor 11/14/17 03:32:29 PM
#36970   Just slapped .0085’s gangsterflavor 11/14/17 03:32:04 PM
#36969   I am adding here as well. My average Upset Wookie 11/14/17 03:30:14 PM
#36968   This will bounce back <.01 very soon.. seen gangsterflavor 11/14/17 03:30:05 PM
#36967   Totally agree. In my opinion, those that Pennyboy20 11/14/17 03:11:44 PM
#36966   Way oversold down here Riley34 11/14/17 02:57:59 PM
#36965   At .0075 and .008, I'll buy. If Pennyboy20 11/14/17 02:50:47 PM
#36964   No volume selling, we must wait for news Riley34 11/14/17 02:49:32 PM
#36963   I see the price dropping, so I certainly Pennyboy20 11/14/17 02:44:14 PM
#36962   Something is happening here, volume pick up, quarterly Riley34 11/14/17 02:00:41 PM
#36961   I would love that outcome. I'm hoping Pennyboy20 11/14/17 01:33:54 PM
#36960   I think you are bang on. Things Riley34 11/14/17 01:07:47 PM
#36959   We will probably test the 200 either today Upset Wookie 11/14/17 12:06:48 PM
#36958   I am waiting as well. I have Pennyboy20 11/14/17 08:53:43 AM
#36957   I like the volume picking up here, this Riley34 11/13/17 03:06:21 PM
#36956   He also specializes in Securities law, so I Pennyboy20 11/13/17 02:13:10 PM
#36955   I would say based on the past that Upset Wookie 11/13/17 01:54:50 PM
#36954   Lots and lots of volume, does anybody know jz8000 11/13/17 01:21:05 PM
#36953   Something is brewing here. Look at the Riley34 11/13/17 12:32:36 PM
#36952   Just announced quarterly will be late Riley34 11/13/17 12:28:18 PM
#36951   Everyone occasionally misses deadlines. If you look at Upset Wookie 11/13/17 11:39:29 AM
#36950   I see, have they ever missed the deadline before? Pennyboy20 11/13/17 10:43:04 AM
#36949   Because they are due Riley34 11/13/17 10:38:25 AM
#36948   Where does it state the financials are coming Pennyboy20 11/13/17 10:37:32 AM
#36947   Don't forget will will get financials this week, Riley34 11/13/17 10:15:45 AM
#36946   We are going to test the 200DMA before Upset Wookie 11/13/17 09:58:15 AM
#36945   Well, it appears we have some volume back, Pennyboy20 11/13/17 09:55:37 AM
#36944   It appears the volume has dried up. Pennyboy20 11/13/17 09:34:34 AM
PostSubject